Regeneron, Sanofi Pull Plug on Aflibercept Trial

September 2009
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p2
The article reports on the decision of Regeneron Pharmaceuticals Inc. and Sanofi-Aventis Group to stop the Phase III trial for aflibercept plus gemcitabine vs. placebo plus gemcitabine in Tarrytown, New York. It states that their decision was driven by the independent data monitoring result indicating the negative impact of the addition of aflibercept to gemcitabine. The group committed to continue to bring effective and new treatments after the result of the study disappointed them.


Related Articles

  • Regeneron, Sanofi-Aventis Start Two Trials.  // Bioworld Week;8/27/2007, Vol. 15 Issue 35, p5 

    The article reports that Regeneron Pharmaceuticals and Sanofi-Aventis will initiate the two Phase III trials of the oncology program for Aflibercept in the U.S. The program involves the evaluation of the safety and efficacy of the drug in combination with standard chemotherapy in patients with...

  • Following Its Expected Launch Next Year in the U.S. and Europe for Second-Line Treatment of Colorectal Cancer, Regeneron/Sanofi's Zaltrap Will Earn Peak-Year Sales of up to $250 Mln.  // Biomedical Market Newsletter;5/16/2011, p390 

    The article reports that Zaltrap from Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA is expected to earn peak-year sales of up to 250 million dollars. It states that a clinical trial on Zaltrap shows that it has improved the overall survival rate in metastatic colorectal cancer (CRC)...

  • Asthma treatment passes trial. Investor's Business Daily // Investors Business Daily;11/12/2014, pA02 

    The article announces the positive results of the phase two of the study for dupilumab in patients with moderate to severe uncontrolled asthma, jointly conducted by pharmaceutical firms Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA.

  • Regeneron, Sanofi Pull the Plug on Aflibercept Pancreatic Trial.  // BioWorld Today;9/14/2009, Vol. 20 Issue 176, p1 

    This article reports on the decision of Regeneron Pharmaceuticals Inc. and partner Sanofi-aventis Group to discontinue their Phase III trial of aflibercept plus gemcitabine versus placebo plus gemcitabine for the first-line therapy of metastatic pancreatic cancer. According to an independent...

  • Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny. AMY REEVES // Investors Business Daily;6/5/2015, p00 

    The article reports on the scrutiny of newest class of cholesterol drug, Praluent, the PCSK9 inhibitor developed by pharmaceutical company, Regeneron Pharmaceuticals and Sanofi by the U.S. Food and Drug Administration for approval. Topics discussed include use of low density lipoproteins (LDL)-C...

  • FDA weighs cholesterol fighter. Investor's Business Daily // Investors Business Daily;6/9/2015, pA02 

    The article reports on the review process to be conducted by the advisory panel of the U.S. Food and Drug Administration (FDA) on the Repatha, a PSCK9 inhibitor from pharmaceutical firm Amgen Inc., used in lowering the cholesterol level on patients. It states that FDA will decide whether Repatha...

  • The price of priority review: $67.5 million. Senior, Melanie // Nature Biotechnology;Oct2014, Vol. 32 Issue 10, p973 

    The article reports on the $67.5 million price for the U.S.Food and Drug Administration's (FDA) priority review voucher (PRV). San Rafael, California-based BioMarin Pharmaceutical Inc. is the first company to publicly sell a PRV, which provides a four-month shortcut through the U.S. drug...

  • 3 Key Biotech Drug Approvals Expected This Month. AMY REEVES // Investors Business Daily;8/12/2015, p00 

    The article reports that several drugs will be approved by the U.S. Food and Drug Administration in the second half of August 2015 which may benefit three biotechnology stocks. These stocks are Amgen Inc., Regeneron Pharmaceuticals Inc., and Sanofi-Aventis SA. Comments from investment analyst...

  • Sentiment 'Swayze' Other Way in Pancreatic; Hopes Escalating. Osborne, Randy // BioWorld Insight;9/21/2009, Vol. 17 Issue 38, p1 

    The article reports on the decision of Sanofi-Aventis Group and Regeneron Pharmaceuticals Inc. to terminate the aflibercept's Phase III trial for the creation of a new treatment for metastatic pancreatic cancer. It mentions that the said disease was the cause of Patrick Swayze's demise and cites...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics